Safdari, Y. and Ahmadzadeh, V. and Farajnia, S.
(2016)
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.
Investigational New Drugs, 34 (4).
pp. 497-512.
Abstract
Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. While it is true that most lymphoma/leukemia patients can be cured, these regimens are limited by the emergence of treatment resistance. Based on these observations, development of anti-CD20 monoclonal antibodies and combination therapies have been recently proposed, in particular with the aim to optimize the cytotoxic activity. Here we outline a range of new experimental agents concerning the CD20 positive B-cell tumors which provide high benefit from conventional therapy. © 2016, Springer Science+Business Media New York.
Actions (login required)
 |
View Item |
